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Abstract
Introduction: Intrathecal baclofen pumps are valuable treatment options for those with cerebral palsy. Although subfascial ba-
clofen pump placement is generally preferred over a subcutaneous pump placement due to lower infection rates, rare complica-
tions can occur with the subfascial approach such as pump migration.
Case Presentation: The authors here describe a case of baclofen pump migration into the peritoneal cavity of a 26-year-old male
patient with cerebral palsy, shunted hydrocephalus, and epilepsy. Because the patient’s pump could not be palpated on exam and
hence refilled, imaging was undertaken, but did not reveal clear evidence of pump migration. Surgery afterward confirmed that the
pump had migrated into the peritoneal cavity through a fascial defect. Baclofen pump had to be replaced instead subcutaneously
as well as the patient later had to be readmitted for 2 ventriculoperitoneal shunt revisions due to progression of his hydrocephalus.
Conclusions: Intraperitoneal migration of a subfascially placed baclofen pump is a rare, yet serious complication, which has been
reported only once in the literature. We advise neurosurgeons to have a low level of threshold in confirming the location of a ba-
clofen pump with imaging and surgical exploration if necessary in order to avoid detrimental outcomes such as bowel perforation.
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1. Introduction
Intrathecal baclofen pumps are commonly used for
the treatment of spasticity in a number of pathologi-
cal processes, including cerebral palsy, stroke, traumatic
brain injury, spinal cord injury, and multiple sclerosis. Var-
ious complications related to these drug delivery systems
have been described in the literature, usually related to
catheter malfunction or pump-catheter connection prob-
lems (1, 2). However, to our knowledge, baclofen pump mi-
gration into the peritoneal cavity has been reported in the
literature only once (3). The authors describe here an inter-
esting case of intraperitoneal baclofen pump migration in
a 26-year-old male patient who originally had his baclofen
pump placed in a subfascial location.
2. Case Presentation
A 26-year-old male patient with a history of spastic cere-
bral palsy, shunted hydrocephalus, and epilepsy was re-
ferred for his baclofen pump refill as well as increasing
discomfort from spasticity. He was being treated with
baclofen administered via an intrathecal baclofen pump
that had been originally placed in subfascial position more
than 20 years ago. His pump had been replaced twice pre-
viously. Specifically, he had undergone one previous end-
of-service pump replacement and one revision to replace
a fractured catheter, and the patient had not experienced
any complications with any of his prior pump refills.
Because the patient’s baclofen pump could not be pal-
pated in the created pocket and he continued to have signs
of spasticity, an X-ray was performed, during his referral
appointment at the clinic. The X-ray demonstrated a sub-
costal location of his baclofen pump, but it wasn’t clear
from the X-ray whether the pump had migrated into the
peritoneal cavity or not (Figure 1).
The patient was subsequently admitted and taken to
the operating room for revision of his baclofen pump.
Upon opening the subfascial pump pocket, we saw the
pump catheter, but unexpectedly noticed that the pump
had migrated. The dissection was extended along the
catheter until the peritoneal cavity was entered where the
40-mL baclofen pump was found (Figure 2).
We removed his pump and inspected the bowel to en-
sure that no perforation had occurred. On further exami-
nation, we identified a fascial tear through which the ba-
clofen pump had migrated. This defect in the fascia was
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Figure 1. X-Ray on Presentation Demonstrating Subcostal Location of Patient’s Sub-
fascially Placed Baclofen Pump
Figure 2. Intraoperative Image Demonstrating Intraperioneal Migration of a Sub-
fascially Placed Baclofen Pump as Evidenced by Pump Being Surrounded by Bowel
in the right lower abdominal quadrant, on the posterior
aspect of the subfascial pump pocket. For this reason, a
smaller (20 mL) baclofen pump was filled and inserted in-
stead subcutaneously.
Following the removal of his migrated baclofen pump
and its replacement with a subcutaneous one, the patient
was discharged home on postoperative day 7 only to re-
turn on postoperative day 9 with constipation and abdom-
inal pain. Subsequently, he was readmitted and placed on
a strict bowel regimen with milk of molasses enema treat-
ments. As his diet was slowly advanced, he was monitored
for any evidence of bowel distension. Once the patient was
able to have normal bowel movements and tolerate oral
food intake, he was discharged home on postoperative day
12. Additionally, on discharge it was noted that the patient
would later need a proximal and distal revision of the ven-
triculoperitoneal shunt for his worsening hydrocephalus.
Due to progression of his hydrocephalus, the patient
was then readmitted for a scheduled proximal and dis-
tal revision of his ventriculoperitoneal shunt. Although
patient had significant adhesions, ventriculoperitoneal
shunt revision was successfully performed. The patient
was observed until postoperative day 7 to exclude the pos-
sibility of his ventriculoperitoneal shunt failure and sent
home in good condition following this second procedure.
However, on postoperative day 22, the patient began to
develop evidence of shunt failure, including headaches
and increasing ventriculomegaly. The patient was subse-
quently readmitted and returned to the operating room
for a second revision of his ventriculoperitoneal shunt.
Unfortunately, approximately one month later the patient
passed away suddenly from what was believed to be sud-
den unexpected death in epilepsy. Of note, he was be-
ing managed with anti-epileptic drugs and intrathecal ba-
clofen has no known effects on seizure exacerbation.
3. Discussion
Baclofen is a gamma-Aminobutyric acid (GABA) B re-
ceptor agonist that is commonly prescribed for the treat-
ment of spasticity (1). Activation of GABAB receptors leads
to inhibition of spinal reflexes, thereby decreasing spas-
ticity. Oral baclofen is an effective treatment for spasticity
as the medication readily crosses the blood brain barrier.
However, side effects with oral baclofen therapy are com-
mon and may include fatigue and sedation. For this rea-
son, intrathecal baclofen is preferred as a targeted therapy
for patients suffering from spasticity (1, 4).
Two common techniques for intrathecal baclofen
pump insertion include subcutaneous and subfascial
pump placement. During subcutaneous placement, a
small pocket is formed in the subcutaneous layer of the
abdominal wall and the intrathecal catheter is tunneled
to this pocket, where it is connected to the pump. Alter-
natively, another surgical technique is to place a baclofen
pump subfascially, but the pump pocket is formed in the
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abdominal wall underneath the anterior rectus abdomi-
nus and the external oblique fascia (5, 6).
When compared to subcutaneous pump placement,
subfascial pump placement is believed to reduce infection
rates, especially in the pediatric population (5, 7). This is
important to consider since higher infection rates over-
all have been demonstrated in children undergoing ba-
clofen pump placement when compared with adults (8).
For these reasons, baclofen pumps are frequently placed
in a subfascial manner especially in the pediatric popula-
tion. Additionally, subfascially placed pumps also tend to
be more cosmetically appealing. Although preferred for
all these reasons, subfascially placed pumps frequently re-
quire fluoroscopy for refills. They can also have serious
complications such as pump migration into the peritoneal
cavity, as described in this case report.
The authors here describe an interesting case of ba-
clofen pump migration into the peritoneal cavity of a 26-
year-old male patient who subsequently died from an un-
expected death in epilepsy. The patient’s pump could not
be palpated on the exam in the created pump pocket and
he was experiencing increasing discomfort from spasticity.
Of note, if an attempt to refill his pump had been made, a
direct perforation of the bowel might have occurred since
surgery later revealed that his pump had migrated into the
peritoneal cavity through a fascial defect. It is essential to
recognize that if there is any uncertainty during the eval-
uation for a patient’s pump refill, the pump should be im-
aged to confirm its current location and ideally compared
to previous images. If there is still uncertainty, surgical ex-
ploration remains essential as in this case.
Our literature search found only one previously re-
ported case of intrathecal baclofen pump migration into
the peritoneal cavity. The authors there hypothesized that
the migration of the pump was related to its placement be-
low the linea semilunaris, leaving only a weak fascial layer
formed by the fascia transversalis between the pump and
the peritoneal cavity (3). In our patient, the subfascially
placed baclofen pump migrated into the peritoneal cavity
in a similar manner. During the exploratory laparotomy
performed on our patient to retrieve the pump, an obvi-
ous fascial defect was also identified at the inferior portion
of the fascia transversalis just above the inguinal ligament
through which the pump had migrated. This defect in the
fascia was in the right lower abdominal quadrant, on the
posterior aspect of the subfascial pump pocket. However,
the underlying mechanism behind pump migration into
the peritoneal cavity remains to be elucidated.
Intrathecal baclofen pumps are valuable treatment op-
tions for those with spasticity from cerebral palsy, stroke,
traumatic brain injury, spinal cord injury, and multiple
sclerosis. Although subfascial pump placement is gener-
ally preferred over subcutaneous pump placement due to
lower infection rate, rare complications can occur such as
pump migration with this approach. Whether this is re-
lated to initial technique of pump insertion below linea
semilunaris or not remains to be elucidated in the future.
Nonetheless, we advise neurosurgeons to maintain a low
level of threshold with regards to confirming the location
of a baclofen pump with imaging and surgical exploration
if its relocation is suspected in order to avoid detrimental
outcomes such as bowel perforation.
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